Mymetics Corp (MYMX)

[Phosphene]

A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge

28 March 2023

"Virosomal vaccines are generally stored refrigerated, but a new thermostable spray-dried powder initially developed for our nasal HIV-1 vaccine remained stable for few months at 40 °C/75% relative humidity without compromising the vaccine bioactivity."

"This new manufacturing process was also applied for the development of a thermostable nasal COVID-19 vaccine, starting with an intermediate product under a liquid form subsequently downstream processed into nasal powder, which is currently under investigation."

https://www.nature.com/articles/s41598-023-31818-y

https://pubmed.ncbi.nlm.nih.gov/36977691/

Funding
This work on NHP (project acronym AVVAX-COVID-19) was supported by TRANSVAC2 grant (2002-08-AVVAX-COVID-19, TRANSVAC2_TNA2002-08), and also financially supported by the BPRC. This study was also sponsored by Mymetics Corporation that is funded through private investments.

Acknowledgements
We thank Carmelina Mahrer and Ronald Kempers for their continuous administrative support and inputs for this project. Special thanks to Mymetics main shareholders that have continuously supported Mymetics team effort. We thank the Animal Science Department at the BPRC for excellent care and handling of the animals. We are grateful to Maria Elena Bottazzi and her team from the Baylor College of Medicine and Texas Children’s Hospital (Texas USA) that has kindly provided the RBD antigen, and their support for this virosomal COVID-19 project. Our thanks also to Mark Tomai from 3M Drug Delivery Systems Division for early discussions about the 3M-052 adjuvant and inputs, and all the other persons involved in the project that were not mentioned.